

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently amended) A method of screening a human subject in need of treatment for a solid epithelial tumor that overexpresses p185^{ErbB2}, as an aid in selecting therapy, comprising determining whether the tumor expresses p95^{ErbB2}, where expression of p95^{ErbB2} indicates said subject is more likely to exhibit a favorable clinical response to treatment that includes GW572016 a p95^{ErbB2} inhibitor, than to treatment that does not include GW572016 a p95^{ErbB2} inhibitor.

2. (Original) A method according to claim 1 where expression of p95^{ErbB2} in tumor tissue is assessed by immunohistochemical methods.

3. (Original) A method according to claim 1 where expression of p95^{ErbB2} is assessed by measuring ErbB2 extracellular domain (ECD) in a sample of the subject's serum.

4 – 5. (canceled)

6. (Original) A method according to claim 1 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors.

7. (Original) A method according to claim 1 where said subject has breast cancer.

8. (Original) A method according to claim 1 where said subject has previously been treated with a p185^{ErbB2} inhibitor.

9. (Original) A method according to claim 1 where said subject has previously been treated with trastuzumab.

10. (Currently amended) A method of treating a subject with a solid epithelial tumor that overexpresses p185^{ErbB2}, comprising determining whether the tumor expresses p95^{ErbB2}, and treating said subject with GW572016 a ~~p95^{ErbB2} inhibitor~~ if said tumor expresses p95^{ErbB2}.

11. (Original) A method according to claim 10 where expression of p95^{ErbB2} in tumor tissue is assessed by immunohistochemical methods.

12. (Original) A method according to claim 10 where expression of p95^{ErbB2} is assessed by measuring ErbB2 extracellular domain (ECD) in the subject's serum.

13. -14. (canceled)

15. (Original) A method according to claim 10 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors.

16. (Original) A method according to claim 10 where said subject has breast cancer.

17. (Original) A method according to claim 10 where said subject has previously been treated with a p185^{ErbB2} inhibitor.

18. (Original) A method according to claim 10 where said subject has previously been treated with trastuzumab.

19. (Canceled)

20. (Currently amended) A method of treating a subject with a solid epithelial tumor ~~whose tumor~~ that expresses p95^{ErbB2}, comprising administering a therapeutically effective amount of GW572016 ~~a p95^{ErbB2} inhibitor~~ to said subject.

21. (Original) A method according to claim 20, where said subject has breast cancer.

22. (canceled)

23. (Original) A method according to claim 20 where said subject has previously been treated with trastuzumab.

24. (Original) A method of treating a subject with breast cancer that is resistant to treatment with a p185^{ErbB2} inhibitor that binds to the extracellular domain of ErbB2 and whose tumor expresses p95^{ErbB2}, comprising administering a therapeutically effective amount of a p95^{ErbB2} inhibitor to said subject.

25. (canceled)

26. (original) A method according to claim 24 where said subject has previously been treated with trastuzumab.

27. (Original) A method of screening a subject in need of treatment for breast cancer to determine suitability for treatment with a p185^{ErbB2} inhibitor that binds to the extracellular domain of ErbB2, comprising determining whether said tumor expresses an elevated level of p95^{ErbB2}, where an elevated level of p95^{ErbB2} indicates that said subject should not be treated with a p185^{ErbB2} inhibitor in the absence of treatment with a p95^{ErbB2} inhibitor.

28. (currently amended) A method according to claim 27, further comprising treating said subject with a treatment selected from (a) a p185^{ErbB2} inhibitor, (b) a combined a p185^{ErbB2} inhibitor and GW572016.

* * *